Revolution Medicines Stock Discussion

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...

$Revolution Medicines (RVMD.US)$ rose more than 10% Wednesday after the biotech firm reported the discovery and preclinical-to-clinical translation of its anti-tumor drug RMC-6236.
RVMD gained 10.6% to close at $36.50 on word of the experimental drug, which the company disclosed in the publication Cancer Discovery.
Revolution disclosed news of the drug on Tuesday shortly before the market closed, sending shares up 3.4% that da...

$Revolution Medicines (RVMD.US)$
Someone just sold 25000 shares. How good they are in timing.

$Revolution Medicines (RVMD.US)$
👀👀 breaking out

Focus Financial Downgraded to Market Perform From Outperform at William Blair
William Blair analyst Jeff Schmitt downgraded $Focus Financial Partners (FOCS.US)$ to Market Perform from Outperform after the company reached an agreement to be acquired by Clayton, Dubilier & Rice and Stone Point Capital in an all-cash transaction valued at $53 in cash per share.
Credit Suisse Upgrades Celsius Holdings to Outperform, Raises Price Target to $...

Gainers:
In reaction to earnings/guidance:
• $Omnicom Group (OMC.US)$ +6.8% (Omnicom reports Q2 EPS $1.68, consensus $1.58)
• $Netflix (NFLX.US)$+6.3% (Netflix executives said they expect 1 million new subscribers to join in the third quarter, with revenue forecast to grow to $7.84 billion from $7.48 billion a year ago)
• $Fulton Financial (FULT.US)$ +4.3% (Fulton Financial reports Q2 EPS 42c, consensus 37c)
• $Abbott Laboratories (ABT.US)$ +0.6% (Ab...